© 1988 by Oxford University Press
Journal of the National Cancer Institute, Vol. 80, No. 1, 30-36,
March 2, 1988
© 1988 Oxford University Press
Postoperative Adjuvant Chemotherapy or BCG for Colon Cancer: Results From NSABP Protocol C-0112
3University of Pittsburgh Pittsburgh, PA.
*NSABP Headquarters, 3550 Terrace St., Room 914, Pittsburgh, PA 15261.
Data are presented from 1,166 patients with Dukes B and C carcinoma of the colon who were entered into the National Surgical Adjuvant Breast and Bowel Project (NSABP) Protocol C-01 between November 1977 and February 1983. Patients were randomized to one of three therapeutic categories: 1) no further treatment following curative resection (394 patients); 2) postoperative chemotherapy consisting of 5-fluorouracil, semustine, and vincristine (379 patients); or 3) postoperative BCG (393 patients). The average time on study was 77.3 months. A comparison between patients receiving postoperative adjuvant chemotherapy and those treated with surgery alone indicated that there was an overall improvement in disease-free survival (P=.02) and survival (P=.05) in favor of the chemotherapy-treated group. At 5 years of follow-up, patients treated with surgery alone were at 1.29 times the risk of developing a treatment failure and at 1.31 times the likelihood of dying as were similar patients treated with combination adjuvant chemotherapy. Comparison of the BCG-treated group with the group treated with surgery alone indicated that there was no statistically significant difference in disease-free survival (P=.09). There was, however, a survival advantage in favor of the BCG-treated group (P=.03). At 5 years of follow-up, patients randomized to the surgery-alone arm were at 1.28 times the risk of dying as were similar patients treated with BCG. Further investigation disclosed that this survival advantage in favor of BCG was a result of a diminution in deaths that were non-cancer related. When analyses were conducted on which events not related to cancer recurrence were eliminated, the survival difference between the BCG and control groups became nonsignificant (P=.40); the cumulative odds at 5 years decreased from 1.28 to 1.10. The findings from this study are the first from a randomized prospective clinical trial to demonstrate that a significant disease-free survival and survival benefit can be achieved with postoperative adjuvant chemotherapy in patients with Dukes B and C carcinoma of the colon who have undergone curative resection. [J Natl Cancer Inst 1988;80:30–36]
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  G. P. Kim, L. H. Colangelo, H. S. Wieand, S. Paik, I. R. Kirsch, N. Wolmark, and C. J. Allegra Prognostic and Predictive Roles of High-Degree Microsatellite Instability in Colon Cancer: A National Cancer Institute-National Surgical Adjuvant Breast and Bowel Project Collaborative Study J. Clin. Oncol., March 1, 2007; 25(7): 767 - 772. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Gill, A. W. Blackstock, and R. M. Goldberg Colorectal Cancer Mayo Clin. Proc., January 1, 2007; 82(1): 114 - 129. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. J. Dignam, B. N. Polite, G. Yothers, P. Raich, L. Colangelo, M. J. O'Connell, and N. Wolmark Body Mass Index and Outcomes in Patients Who Receive Adjuvant Chemotherapy for Colon Cancer. J Natl Cancer Inst, November 15, 2006; 98(22): 1647 - 1654. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I Chau and D Cunningham Adjuvant therapy in colon cancer--what, when and how? Ann. Onc., September 1, 2006; 17(9): 1347 - 1359. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A M M Haydon, R J MacInnis, D R English, and G G Giles Effect of physical activity and body size on survival after diagnosis with colorectal cancer Gut, January 1, 2006; 55(1): 62 - 67. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. J. Sargent, H. S. Wieand, D. G. Haller, R. Gray, J. K. Benedetti, M. Buyse, R. Labianca, J. F. Seitz, C. J. O'Callaghan, G. Francini, et al. Disease-Free Survival Versus Overall Survival As a Primary End Point for Adjuvant Colon Cancer Studies: Individual Patient Data From 20,898 Patients on 18 Randomized Trials J. Clin. Oncol., December 1, 2005; 23(34): 8664 - 8670. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. J. Chua, D. Sargent, and D. Cunningham Definition of disease-free survival: this is my truth-show me yours Ann. Onc., November 1, 2005; 16(11): 1719 - 1721. [Full Text] [PDF]
|
|
|
|
|
|
K. Ohrling, D. Edler, M. Hallstrom, P. Ragnhammar, and H. Blomgren Detection of Thymidylate Synthase Expression in Lymph Node Metastases of Colorectal Cancer Can Improve the Prognostic Information J. Clin. Oncol., August 20, 2005; 23(24): 5628 - 5634. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Chau, A. R. Norman, D. Cunningham, D. Tait, P. J. Ross, T. Iveson, M. Hill, T. Hickish, F. Lofts, D. Jodrell, et al. A randomised comparison between 6 months of bolus fluorouracil/leucovorin and 12 weeks of protracted venous infusion fluorouracil as adjuvant treatment in colorectal cancer Ann. Onc., April 1, 2005; 16(4): 549 - 557. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. A. Poplin, J. K. Benedetti, N. C. Estes, D. G. Haller, R. J. Mayer, R. M. Goldberg, G. R. Weiss, S. E. Rivkin, and J. S. Macdonald Phase III Southwest Oncology Group 9415/Intergroup 0153 Randomized Trial of Fluorouracil, Leucovorin, and Levamisole Versus Fluorouracil Continuous Infusion and Levamisole for Adjuvant Treatment of Stage III and High-Risk Stage II Colon Cancer J. Clin. Oncol., March 20, 2005; 23(9): 1819 - 1825. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Figueredo, M. L. Charette, J. Maroun, M. C. Brouwers, and L. Zuraw Adjuvant Therapy for Stage II Colon Cancer: A Systematic Review From the Cancer Care Ontario Program in Evidence-Based Care's Gastrointestinal Cancer Disease Site Group J. Clin. Oncol., August 15, 2004; 22(16): 3395 - 3407. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. B. Benson III, D. Schrag, M. R. Somerfield, A. M. Cohen, A. T. Figueredo, P. J. Flynn, M. K. Krzyzanowska, J. Maroun, P. McAllister, E. Van Cutsem, et al. American Society of Clinical Oncology Recommendations on Adjuvant Chemotherapy for Stage II Colon Cancer J. Clin. Oncol., August 15, 2004; 22(16): 3408 - 3419. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Grem Adjuvant Therapy for Colon Cancer: A Historical Perspective J Natl Cancer Inst, August 4, 2004; 96(15): 1116 - 1117. [Full Text] [PDF]
|
|
|
|
|
|
R. E. Smith, L. Colangelo, H. S. Wieand, M. Begovic, and N. Wolmark Randomized Trial of Adjuvant Therapy in Colon Carcinoma: 10-Year Results of NSABP Protocol C-01 J Natl Cancer Inst, August 4, 2004; 96(15): 1128 - 1132. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Efficacy of Oral Adjuvant Therapy After Resection of Colorectal Cancer: 5-Year Results From Three Randomized Trials J. Clin. Oncol., February 1, 2004; 22(3): 484 - 492. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. Mazzaferro, J. Coppa, M. G. Carrabba, L. Rivoltini, M. Schiavo, E. Regalia, L. Mariani, T. Camerini, A. Marchiano, S. Andreola, et al. Vaccination with Autologous Tumor-derived Heat-Shock Protein Gp96 after Liver Resection for Metastatic Colorectal Cancer Clin. Cancer Res., August 1, 2003; 9(9): 3235 - 3245. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Chau and D. Cunningham Chemotherapy in colorectal cancer: new options and new challenges Br. Med. Bull., December 1, 2002; 64(1): 159 - 180. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Summerhayes Capecitabine: a novel, orally administered, tumour-activated treatment for colorectal cancer Journal of Oncology Pharmacy Practice, December 1, 2001; 7(4): 107 - 125. [Abstract] [PDF]
|
|
|
|
|
|
J. J. Dignam, L. Colangelo, W. Tian, J. Jones, R. Smith, D. L. Wickerham, and N. Wolmark Outcomes Among African-Americans and Caucasians in Colon Cancer Adjuvant Therapy Trials: Findings From the National Surgical Adjuvant Breast and Bowel Project J Natl Cancer Inst, November 17, 1999; 91(22): 1933 - 1940. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Mamounas, S. Wieand, N. Wolmark, H. D. Bear, J. N. Atkins, K. Song, J. Jones, and H. Rockette Comparative Efficacy of Adjuvant Chemotherapy in Patients With Dukes' B Versus Dukes' C Colon Cancer: Results From Four National Surgical Adjuvant Breast and Bowel Project Adjuvant Studies (C-01, C-02, C-03, and C-04) J. Clin. Oncol., May 1, 1999; 17(5): 1349 - 1349. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Efficacy of Adjuvant Fluorouracil and Folinic Acid in B2 Colon Cancer J. Clin. Oncol., May 1, 1999; 17(5): 1356 - 1356. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Summerhayes Raltitrexed and the treatment of advanced colorectal cancer Journal of Oncology Pharmacy Practice, December 1, 1996; 2(4): 225 - 235. [Abstract] [PDF]
|
|
|
|
 |
|
 M. L Slevin Adjuvant treatment for colorectal cancer BMJ, February 17, 1996; 312(7028): 392 - 393. [Full Text]
|
|
|
|
 |
|
 C. G. Moertel Chemotherapy for Colorectal Cancer N. Engl. J. Med., April 21, 1994; 330(16): 1136 - 1142. [Full Text]
|
|
|
|
 |
|
 W. Lawrence Jr Some Problems With Clinical Trials: James Ewing Lecture Arch Surg, March 1, 1991; 126(3): 370 - 378. [Abstract] [PDF]
|
|
|
|
 |
|
 B. Levin and M. J. O'Connell Colorectal Cancer Chemotherapy: Meta-analysis or Large-Scale Trials? JAMA, June 24, 1988; 259(24): 3611 - 3611. [Abstract] [PDF]
|
|